LHRH and its analogues produce profound antireproductive effects in both sexes of a variety of animal species. Although the LHRH agonists induce gonadotropin release, gonadal steroid secretion, ovulation, and spermatogenesis as an expression of their traditional profertility pharmacologic profile, they paradoxically and characteristically cause predominant antifertility effects which have been extensively evaluated for potential contraceptive purposes. These agonists produce their antireproductive effects in both males and females by common mechanisms, ultimately resulting in disruption of pituitary-gonadal function, depression of steroidogenesis, and inhibition of target organs dependent on such gonadal support. Similar antireproductive effects have been observed with the LHRH antagonists which competitively inhibit LHRH-induced gonadotropin secretion resulting in reduced blood gonadal steroid levels. Use of the inhibitory properties has been extended to cancer therapy based on the ability of the LHRH analogues (particularly the agonists) to inhibit the growth of steroid-dependent (responsive) tumors (e.g., mammary, prostate) similar to that produced by gonadectomy and antisteroid treatments. The use of these peptides for selected hormone-sensitive tumors presents a novel pharmacotherapeutic application for this class of drug.
INTRODUCTION
The extensive pharmacologic evaluation of luteinizing hormone releasing hormone (LHRH) and its numerous analogues (agonists and antagonists) has clearly established the antireproductive properties of this class of compound [1] [2] [3] [4] [5] . The paradoxical antifertility activity and high potency of the agonists, in particular, are well-documented and have provided the basis for a new contraceptive approach in both females and males. However, it is only within the last few years that quantities of antagonists with sufficient potency have become available to permit their more detailed pharmacologic evaluation. A general scheme showing these relationships is presented in Fig. 1 .
LHRH and its more potent congeners ("super" agonists) possess the traditional profertility property of inducing pituitary follicle stimulating hormone (FSH) and luteinizing hormone (LH) release, which are, in turn, responsible for ovulation, spermatogenesis, and gonadal steroid secretion. However, using various dosing regimens and routes of administration in animal experiments and in clinical trials, these peptides invariably produced paradoxical antireproductive effects. This apparent contradictory but predictable contraceptive activity has been repeatedly demonstrated in a wide variety of studies [1] [2] [3] [4] [5] . Numerous have become available since LHRH was isolated, identified, and synthesized in 1971, have been used to demonstrate that the traditional agonist properties are characteristically correlated with and predictable of their antifertility effects. The ability of these compounds to inhibit or impede ovarian and testicular steroidogenesis, and consequently produce regression of the reproductive structures dependent on such steroid support, led to the concept that gonadal steroid-dependent (responsive) tumors might also be affected in a manner analogous to that produced by gonadectomy or by antiandrogenic or antiestrogenic drugs.
This review will describe, for the most part, the basic principles and developments supporting the paradoxical antireproductive effects of the LHRH agonists, current concepts regarding the mechanisms that are involved and the application of these properties as potential therapeutic antitumor agents. A brief reference will be made to the LHRH antagonists which also possess antireproductive properties but have been demonstrated only recently to produce antitumor effects.
LHRH AGONISTS PROPERTIES: TRADITIONAL AND PARADOXICAL ANTIFERTILITY EFFECTS LHRH and its agonistic derivatives stimulate the pituitary-gonadal target organ axis under physiological and carefully regimented pharmacologic conditions in females and males.
In contrast, numerous studies [1] have demonstrated that the parent molecule, LHRH, was capable of terminating pregnancy when administered to inseminated rats either preimplantationally (claudogen test, days 1-7) or postimplantationally (interceptive test, days [7] [8] [9] [10] [11] [12] . This paradoxical antifertility effect gained prominence when it was demonstrated that several synthetic congeners produced similar effects at considerably lower doses. Subsequently, it was established that such antireproductive consequences were consistently associated with the ability of this class of peptide to release LH (and induce ovulation); these basic profertility effects served to identify and predict those LHRH agonists with contragestational (and eventually broad antireproductive) activity and enhanced potency. The amino acid sequence of LHRH and representative structural modifications that were made to yield some of the more potent agonists are shown in Fig. 2 . The various agonists receiving significant attention and their dual properties (ovulation induction and postcoital contraception) from studies in the rat are listed in Table 1. Table 2 action, that have been reported in the animal and clinical literature. As noted in Table 2 , these agents can also produce extra-pituitary effects, adding another dimension to their proposed mechanism(s) of action. Table 3 illustrates the laboratory observations with the Wyeth compound, Wy-40,972, which possesses a reproductive and safety profile characteristic of the LHRH agonist class.
The LHRH agonists, by impeding gonadal steroidogenesis, produce regression of D-AIa6-Des-GIyI0-Pro9-NHEt-LH-RH ity as antitumor agents in a manner akin to that produced by antiestrogenic (e.g., Tamoxifen) [6] and antiandrogenic (e.g., Cyproterone acetate) [7] DesGlyl0-Pro9-NHEt-LHRH ..500
percent of the DMBA tumors regressed and, of these, 50 percent disappeared. Withdrawal of analogue for a period of four weeks led to tumor regrowth and to the appearance of new tumors. The antitumor effect of the peptide was equivalent to that of ovariectomy, suggesting that support of the tumor was estrogen-dependent. The studies by Nicholson and colleagues [10] [11] [12] and Lamberts et al. [13] in the rat showed that the agonist, D-Ser(TBU)6-AzGly10-LHRH, also was capable of causing regression of DMBA-induced mammary tumors and of estrogen-induced transplantable prolactin (PRL)-secreting rat pituitary tumors (7315A), respectively. In these studies, the tumor-inhibiting effects of the compound were associated with a general reduction in blood levels of estradiol and prolactin; overall, the antitumor results were similar to those observed with Tamoxifen treatment or ovariectomy.
Corbin et al. [14] reported that the development of tumors in four-day-old hamsters inoculated with virulent mouse mammary tumor (MMT) cells was impeded by parenteral administration of either LHRH or D-Ala6-DesGly10-Pro9-NHEt-LHRH (Wy-18,481) for a period of ten days (Fig. 6 ). Tumor size remained depressed during the five days following cessation of treatment. It is noteworthy that this tumor retardation occurred during suppression of the animal's own immune defense system, since these recipients were treated with antilymphocytic serum (ALS) on two occasions during the study. Thus, the peptides attenuated tumor growth under conditions which tended to promote maximal tumor growth. Kelly et al. [15] and Turcot-Lemay et al. [ISa] , utilizing the same LHRH agonist chronically, demonstrated similar effects on DMBA-induced tumors in rats, associated with significant increases in blood levels of LH and FSH, and a dramatic decline in progesterone and prolactin levels. These investigators suggested that LHRH agonists produce a "functional" castration, such effects being consistent with antifertility effects observed by others. These collective results reinforce the concept that the reduction of the number of tumors and the tumor regression produced by chronic treatment with these peptides is analogous to that observed following ovariectomy or treatment with the antiestrogen, Tamoxifen [8] [9] [10] ; furthermore, cessation of peptide treatment can lead to a recrudescence of the tumor, which upon reinitiation of treatment, once again is followed by tumor regression [9] . These data underline the requirement for uninterrupted or chronic intermittent administration of these compounds.
The predominant mechanism by which pharmacologic and sustained doses of LHRH and agonists produce their antireproductive manifestations is via initial hypersecretion of pituitary LH and subsequent downregulation of gonadal receptors for LH, FSH, and PRL (decreased receptor numbers), eventually followed, with chronic administration, by pituitary desensitization and overall inhibition of gonadal steroidogenesis. In contrast, the antisteroidal drugs (e.g., Tamoxifen, (Cyproterone acetate) can act by blocking the effect of endogenous gonadal steroids directly at the target organ receptor, interfering with the cytoplasmic/nuclear steroid expression at the cellular level [6, 7] . Thus, while the mechanisms of action of the LHRH agonists and those of the classical antiestrogens and antiandrogens are different, the end result is the same: interruption of steroid support for the tumor.
Additionally, there are data supporting extrapituitary, direct gonadal or direct gonadal target organ effects of these peptides [16] . In view of the possibility that LHRH agonists also may act directly on the tumor, we performed a dose-response study in which mouse mammary tumor cells were subjected, in vitro, to Wy-40,972 for seven days. The results (unpublished), described in Fig. 7 , reveal a tendency toward a dose-related retardation in the increase of the viable cell population. However, after the fourth day of treatment, in spite of continuing exposure to the peptide, the number of viable cells reaches control levels. Because these cells grow so rapidly, relatively high doses of the agonist were required. The rapid growth pattern is further observed beyond the seventh day; a growth plateau eventually is reached followed by a rapid decline in the viable population and ensuing morbidity as the cells simply exhaust their limited environment. These preliminary results suggest the possibility of a direct effect of the agonist on the tumor.
In the studies reported by Rose and Pruitt [17, 18] the LHRH agonist, Leuprolide, caused regression of rat mammary tumors induced by DMBA or by N-nitrosomethylurea (NMU); such tumors also responded favorably to ovariectomy or Tamoxifen treatment. Similar results were obtained by Danguy et al. [19] who also utilized Leuprolide in DMBA-induced tumor-bearing rats. In addition, these investigators showed that six weeks of treatment not only produced mammary tumor regression but also atrophy of pituitary lactotropes and decreases serum prolactin concentrations, the latter effect having been observed by several of the other investigators. It is clear that treatment with several of the LHRH agonists produce their palliative effects on several types of experimentally induced tumors by minimizing or removing the supportive effect of estrogen, thereby mimicking the effects obtained with ovariectomy or antiestrogen therapy.
The role of prolactin in supporting mammary tumor growth and its modification by the agonists is an important point of consideration. Prolactin may have a direct effect on the tumor itself or act through its ability to increase estrogen receptor content or stimulate estrogen secretion. Thus, prolactin may play a permissive role in mammary tumor growth and that it is the estrogen (and perhaps other ovarian steroids) upon which the tumor depends. Furthermore, the degree to which prolactin plays a promotional or supportive role may be a function of the nature of the mammary tumor itself. The results of Danguy et al. [19] showed that while Leuprolide produced a greater suppression of serum prolactin levels than did ovariectomy, the peptide was less effective than ovariectomy in suppressing tumor growth. With regard to the Rose and Pruitt studies [17, 18] the anti-DMBA-induced tumor effect of Leuprolide was impeded when estradiol benzoate was administered concomitantly. Moreover, when perphenazine (a phenothiazine which produces hyperprolactinemia) also was administered with Leuprolide, the antitumor efficacy of the latter likewise was impaired. It was suggested that the peptide produced its antitumor effect through initial inhibition of ovarian steroidogenesis with consequential hypoprolactinemia. In contrast, while Leuprolide caused regression of rat tumors induced by NMU, its effectiveness was inhibited by estradiol benzoate but not by perphenazine [18] . These investigators suggested that NMU-induced tumors are estrogen rather than prolactin-dependent, with the analogue producing a pharmacologic ovariectomy; additionally, they proposed that NMU-induced mammary tumors reflect the clinical disease state which is not responsive to prolactin inhibitors such as 2-Br-a-ergocryptine [20] .
It is difficult to discern the degree to which estrogen or prolactin contributes to mammary tumor genesis and maintenance. DMBA-induced mammary tumors obviously are hormone-dependent and will regress following ovariectomy or hypophysectomy [21] . Kelly et al. [15] Chronic administration of LHRH or agonists produce a loss of testicular LH and prolactin receptors, decreased androgen synthesis and blood levels, a reduction in the weight of the testes, testicular histologic disorganization, inhibition of spermatogenesis, and reduced weights of the sexual accessory apparatus [32, 37] . Thus, the eventual decrease in androgen secretion observed in LHRH-agonist-treated animals provided the basis for the potential use of these peptides, either alone or as an adjunct to other therapies, in androgen-dependent pathologies in the human male.
Redding and Schally [38, 39] Preliminary results from our laboratory (unpublished) reinforce the antitumor effect of the LHRH antagonists. Neonatal hamsters were inoculated with MMT cells (and ALS) as previously described [14] and intermittently treated parenterally with the LHRH antagonist, AC-dehydroPro1-pF-D-Phe2-D-Trp3'6-LHRH (Wy-44,599; obtained from the Salk Institute), over a period of ten days. The data in Fig. 8 50 -100 Itg of the latter, to males for 6-20 weeks, produced the predictable declines in LH, FSH, testosterone, dihydrotestosterone, and in estrone and estradiol. Decrease of prostatic mass and improvement of urinary outflow obstruction were documented. In the more detailed report Tolis et al. [50] treated ten geriatric patients with prostatic carcinoma (four with severe incapacitation due to pain; two with disseminated osteoblastic metastases; two with urinary flow obstruction) with either D-Trp6-LHRH (100 A4g/day, subcutaneously) or Buserelin (50 itg/day, subcutaneously or 500 ,^4g twice daily) for six weeks to 12 months. In general, patients experienced significant clinical improvement. In addition to achieving a "medical castration" (significant suppression of blood levels of testosterone and estradiol) there was relief of pain, decline in acid and alkaline phosphatase levels, improvement of urinary outflow obstruction and bone lesions (evidenced by isotopic bone imaging), and reduced prostatic mass (documented by ultrasonography). There results, although derived from a very small population, are encouraging for they indicate the potential use of the LHRH agonists in ameliorating the progress of a disabling prostatic malignancy.
Harvey et al. [51 ] and Warner and associates [52] [53] [54] carried out a series of studies with Leuprolide on patients with postmenopausal advanced breast cancer or prostatic carcinoma. The 31 female subjects, most of whom had received prior therapy for metastatic mammary carcinoma and who were either estrogen receptor positive (ER +) or antihormone responsive, were administered a daily subcutaneous dose of 1.0 to 5.0 mg of the agonist for up to 30 weeks. Heterogeneous effects were obtained: 16 percent showed objective responses; 19 percent were stabilized, and 65 percent had disease progression. Remissions in the responder group lasted from 12 to 30 weeks. No side effects of the drug were obvious; however, it was not known what role the initial therapy played in influencing the outcome of the trial with the agonist.
In the male investigation, 57 patients with prostatic cancer were administered the analogue (1.0-10 mg/day, subcutaneously) for eleven weeks. An initial study in the androgen-dependent rat prostate tumor model (Noble adenocarcinoma) [55] demonstrated that chronic administration of the agonist produced decreased size of the prostate, seminal vesicle, and testes; reduction of blood levels of LH, FSH, and testosterone; inhibition of 17a-hydroxylase and C-17,20 lyase activity; induction of 5a-reductase and 3-keto-reductase activity and direct inhibition of testicular LH receptor numbers. The authors reported that the clinical data paralleled those derived from the animal study: gonadotropin levels were markedly suppressed and testosterone decreased to levels comparable to those found in the 31 castrate control subjects with prostate tumors. Additionally, dihydrotestosterone and 3a-androstanediol values were reduced and objective tumor regression was observed. Based on these clinical results and the analogous antiandrogenic/antitumor effects in the animal model, these investigators emphasized the value of primary treatment of prostatic carcinoma employing the "medical castration" effect of the agonist as an alternative to surgical orchiectomy [54] .
A generalized scheme of the possible mechanisms of action of LHRH agonists on tumor regression is depicted in Fig. 9 . The mechanisms by which the LHRH analogues inhibit tumor growth may be numerous. The major mechanism of the agonists appears to be via pituitary-gonadal downregulation and desensitization: the LHRH agonist induces initial gonadotropin hypersecretion that leads to gonadal gonadotropin receptor loss and reduced steroidogenesis; continuous agonist administration results in hypophysial desensitization and LHRH receptor downregulation leading to blunted secretion and decreased blood levels of gonadotropins producing a further suppression of steroidogenesis and removal of steroid support for the tumor. Additionally, the shift in steroidogenic patterns due to interference with the enzymes responsible for precursor conversion may lead to a decrease or an increase of a particular steroid (e.g., excess progesterone in the male).
The reduced serum levels of gonadotropins, prolactin, and the androgenic and estrogenic steroids are representative of "selective hypophysectomy" or of castration, procedures that can be effective in arresting the growth of particular tumors. Moreover, the agonist may have effects directly on the gonad since the testes and ovaries have been shown to possess LHRH receptors [16] , or directly on the tumor itself (e.g., prostate), although there are conflicting data supporting the presence of LHRH receptors in secondary sex organs.
Of interest, however, is the report of Sundaram et al. [56] demonstrating that LHRH agonists could block the stimulatory effect of exogenous sex steroids on accessory reproductive organs in castrated and/or hypophysectomized male and female rats. These results suggested that the analogue could directly antagonize the effect of sex steroids at the target organ level.
Preliminary data on the LHRH antagonists indicate that these LHRH derivatives can also inhibit tumor growth. The mechanism of the LHRH antagonists is via competitive inhibition of pituitary LHRH receptors, preventing endogenous LHRH stimulation of pituitary gonadotrophs and gonadotropin secretion, subsequently leading to depressed gonadal steroidogenesis.
Several questions arise regarding the nature of the tumor that would be susceptible to LHRH analogue intervention, the dosing regimens, whether these peptides are to be administered solely or as adjuncts to established therapies, and routes of administration. The presence of high concentrations of gonadal steroid receptors (and perhaps even those for prolactin) in various neoplasias (e.g., estrogen receptorpositive) is used as a marker to judge if a tumor is a candidate for antihormone therapy [26] . In numerous instances, tumors are composed of heterogeneous cell populations, each subset possessing different physiologic properties, and varied metastatic potential and susceptibility to various modes of therapy [57] . Receptors for estrogen, androgen, and progestagen have been found in tumors of reproductive origin (e.g., mammary, endometrial, ovarian, prostatic); the presence of all or of some of these receptors in primary and metastatic tumor tissue has been utilized to determine if antihormone therapy would be appropriate. Tumor receptor concentrations may not only dictate the nature of the treatment but they can be of prognostic value in terms of recurrence and survival, especially with regard to the presence of estrogen receptors in breast and endometrial carcinomas [27, [58] [59] [60] [61] . However, it should be realized that only approximately 50 percent of breast cancers that are deemed estrogen receptor positive respond to ablative or endocrine therapy; this perplexity complicates the view that an ER + tumor condition can be clearly related to not only the hormonal factors that are supporting the tumor but also to its projected management [61a] .
Non-reproductive organ tumors (e.g., renal cell carcinoma) or ectopic tumors (e.g., chorionic gonadotropin-secreting lung carcinoma), which may possess gonadal steroid receptors, also may benefit from antihormone/LHRH analogue therapy [62] [63] [64] .
The possibility that the LHRH agonists may act directly on the tumor (i.e., extragonadal reproductive tissue) remains an intriguing proposition [16] . The in vitro study of Meyskens et al. [65] revealed that human melanoma tumor stem cells can specifically bind LH and that the gonadotropin also could suppress cell growth. These authors suggested that LH may modulate the growth of human melanoma cells and that control of LH levels may have clinical utility in this disease. Conceivably, LHRH agonists, per se, may have direct antitumor effects, by substituting for LH [16] and also by virtue of their ability to cause LH release under carefully controlled chronic regimens (i.e., pulsatile delivery in treatment of hypogonadotropic hypogonadal disorders), they may be of therapeutic value in a broader range of neoplastic diseases. However, the role of LH in breast cancer is unknown.
Zumoff et al. [65a] have proposed that subnormal LH levels and its abnormal diurnal patterns may be associated with increased risk of breast cancer, subserved by hypothalamic dysfunction.
Limited clinical information exists on dosing regimens, use as adjunctive therapy, and routes of administration. However, it would appear from the available animal and human experiences that continuous treatment with the LHRH analogues would be required to maintain a condition of tumor abeyance; the animal investigations clearly indicate that interruption of treatment will lead to tumor recrudescence. Since antisteroidal and LHRH agonist interventions are not cytotoxic (i.e., tumorcidal), other traditional approaches (surgery, radiation, chemotherapy) might be required; the LHRH analogue would play an adjunctive, palliative role, perhaps minimizing the requirements for and the toxic side effects of radiation or chemotherapy, retarding metastases, or reducing tumor size to provide more favorable conditions for surgery.
The possibility that the LHRH agonists may provide a "sparing" effect on chemotherapeutic requirements and/or their damaging side effects has been suggested by Glode et al. [66] . Alkylating antineoplastic agents such as cyclophosphamide (Cytoxan) cause severe damage to the rapidly dividing germinal epithelium of the gonads [66a]. In order to reduce the sensitivity of these highly proliferative cells to the deleterious effects of the chemotherapeutic agent, the pituitary-testicular axis of mice was suppressed by chronic administration with Leuprolide. While Cytoxan alone produced tubular and epithelial disorganization and disrupted morphology, the addition of the LHRH agonist protected against these effects. Interestingly, mice treated with only the Leuprolide showed normal testicular cytoarchitecture. It has been reported that the male mouse is highly resistant to the antireproductive effects of LHRH agonists [67] at doses in considerable excess of those producing rapid and dramatic disruption of reproductive processes in the rat [1, 32, 33] . The mechanism by which the agonist protects spermatogenesis at the level of the seminiferous tubule against the damaging effects of the cytotoxic agent is not certain; such effects may be manifested indirectly via gonadotropin suppression with low doses of the agonist, sparing germinal cell function, or directly on the testis itself. However, it should be noted that any extra-pituitary, direct testicular effect could be exerted only through the Leydig cells, since this is the only compartment possessing detectable LHRH receptors [68] . Irrespective of these confounding factors, the study of Glode et al. [66] suggests the potential ancillary antitumor use of LHRH agonists.
It has been proposed by Auclair et al. [37] that native LHRH could be used for benign prostatic hyperplasia, since LHRH has minimal and therefore less disruptive consequences on testicular tissue. On the other hand, the potent LHRH agonists would be employed, because of their more rapid, prominent, and protracted desensitizing and downregulatory effects on the pituitary-gonadal axis, for the more fulminating neoplasias (prostatic and breast carcinoma) where a "pharmacologic castration" would be desired.
The present modes of clinical administration include subcutaneous and nasal spray delivery. Although the LHRH agonists have been shown to be orally active, the large doses that would be required are impractical. In fact, some of the subcutaneous doses that have been used in the human breast and prostatic cancer studies are in the milligram range; even at these relatively high doses, the human mammary carcinoma trials, in contrast to the prostate studies, have not been encouraging. The nasal spray approach appears to be a reasonable alternative to traditional parenteral dosing methods, having a high degree of patient compliance that has been demonstrated in long-term clinical contraceptive evaluation of these peptides [1] . Another suggested mode of delivery is the transdermal one akin to that used for medicating angina patients with nitroglycerin.
CONCLUSIONS
The antifertility properties of the LHRH analogues provide a novel approach to hormonotherapy of cancer. The LHRH agonists and the antagonists can disrupt pituitary-gonadal function and suppress steroidogenesis, resulting in removal of support for gonadal steroid-dependent reproductive structures. The collective animal and clinical data support the contention that these compounds (particularly the LHRH agonists) may be useful drugs for the treatment of gonadal-steroid dependent tumors or as therapeutic adjuncts to traditional procedures including surgical extirpation, chemotherapy, radiation, and antigonadal steroidal medication by an effect that is tantamount to a "pharmacologic castration."
The LHRH agonists may be of restricted therapeutic value in those cases of breast tumors that are overtly estrogen receptor-positive. By analogy, a similar view might apply to the treatment of prostatic tumors that would require an androgen (and/or estrogen) receptor-positive dimension [69] [70] [71] . However, neoplasias of a general reproductive target category, possessing additional receptors for prolactin, progesterone, LH, and LH-like hormones (e.g., HCG), may be responsive candidates for LHRH agonist intervention. Furthermore, because of the heterogeneous nature of tumor cell populations, non-reproductive neoplasias also possessing the above array of receptors may be likely candidates.
Finally, the role of growth hormone (GH) in supporting tumor growth should be noted. It has been suggested that elimination of prolactin and GH (because the latter is both growth-promoting and lactogenic and binds to prolactin receptors) may have therapeutic utility in breast cancer [31,31c,72] . To this end, a combination of an LHRH agonist plus somatostatin (or an analogue) might be employed to produce a "medical hypophysectomy," simultaneously suppressing the secretion of gonadotropins, prolactin, gonadal steroids and growth hormone (DP Rose, personal communication).
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